ARTICLE SUMMARY:
As competition heats up in the continuous glucose monitor market, Bergen, Norway-based Lifecare sees opportunities for innovation and growth in the implantable CGM segment.
Numerous studies have shown that continuous glucose monitors (CGMs) can improve diabetes management, increasing time in range and preventing dangerous low blood sugar events. But external CGMs also have drawbacks that limit their appeal. They must pierce the skin and be worn on the body, often in a noticeable place. They require a reader—usually a smartphone—be kept close by to stay connected and read the Bluetooth signal. And they must be replaced at least every two weeks, which adds to their cost and inconvenience.
Implantable CGMs that can be left in place for extended periods may appeal to some users, but existing devices still leave room for improvement. And that opens the door for innovative competitors such as Lifecare ASA, based in Bergen, Norway, which believes its unique nanoscale implantable sensor technology can help meet the need for a more patient-friendly, cost-effective solution.
